메뉴 건너뛰기




Volumn 5, Issue 9, 2004, Pages 1957-1964

After ALLHAT: Doxazosin for the treatment of benign prostatic hyperplasia

Author keywords

Alfuzosin; Benign prostatic hyperplasia; Doxazosin GITS; Doxazosin standard; Finasteride; Tamsulosin

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN MESYLATE; DUTASTERIDE; FINASTERIDE; NORADRENALIN; PHENYLEPHRINE; PLACEBO; PRAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 4544344681     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.9.1957     Document Type: Article
Times cited : (6)

References (38)
  • 1
    • 0034685403 scopus 로고    scopus 로고
    • Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)
    • ALLHAT COLLABORATIVE RESEARCH GROUP
    • ALLHAT COLLABORATIVE RESEARCH GROUP: Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA (2000) 283:1967-1975.
    • (2000) JAMA , vol.283 , pp. 1967-1975
  • 2
    • 0345967847 scopus 로고    scopus 로고
    • Impact of clinical trials results on national trends in α-blocker prescribing, 1996-2002
    • STAFFORD RS, FURBERG CJ, FINDKELSTEIN SN et al.: Impact of clinical trials results on national trends in α-blocker prescribing, 1996-2002. JAMA (2004) 291:54-62.
    • (2004) JAMA , vol.291 , pp. 54-62
    • Stafford, R.S.1    Furberg, C.J.2    Findkelstein, S.N.3
  • 3
    • 0030579074 scopus 로고    scopus 로고
    • The α-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate
    • HETANO A, TANG R, WALDEN PD, LEPOR H: The α-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate. Eur. J. Pharmacol. (1996) 313:135-143.
    • (1996) Eur. J. Pharmacol. , vol.313 , pp. 135-143
    • Hetano, A.1    Tang, R.2    Walden, P.D.3    Lepor, H.4
  • 4
    • 0035148442 scopus 로고    scopus 로고
    • α-Blockade downregulates myosin heavy chain gene expression in human benign prostatic hyperplasia
    • LIN VK, BENAIM EA, MCCONNELL JD: α-Blockade downregulates myosin heavy chain gene expression in human benign prostatic hyperplasia. Urology (2001) 57:170-175.
    • (2001) Urology , vol.57 , pp. 170-175
    • Lin, V.K.1    Benaim, E.A.2    Mcconnell, J.D.3
  • 5
    • 0032861498 scopus 로고    scopus 로고
    • α1-Adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia
    • CHON JK, BORKOWSKI A, PARTIN AW et al.: α1-Adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J. Urol. (1999) 161:2002-2008.
    • (1999) J. Urol. , vol.161 , pp. 2002-2008
    • Chon, J.K.1    Borkowski, A.2    Partin, A.W.3
  • 6
    • 0032426688 scopus 로고    scopus 로고
    • Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia
    • KYPRIANOU N, LITVAK JP, BORBOWSKI A, ALEXANDER R, JACOBS SC: Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J. Urol. (1998) 159:1810-1815.
    • (1998) J. Urol. , vol.159 , pp. 1810-1815
    • Kyprianou, N.1    Litvak, J.P.2    Borbowski, A.3    Alexander, R.4    Jacobs, S.C.5
  • 11
    • 0036328850 scopus 로고    scopus 로고
    • Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasia
    • SUN Y, MALOSSI J, JACOBS SC, CHAI TC: Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasia. Urology (2002) 60:351-356.
    • (2002) Urology , vol.60 , pp. 351-356
    • Sun, Y.1    Malossi, J.2    Jacobs, S.C.3    Chai, T.C.4
  • 12
    • 0032923005 scopus 로고    scopus 로고
    • Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia
    • FAWZY A, VASHI V, CHUNG M et al.: Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Urology (1999) 53:329-335.
    • (1999) Urology , vol.53 , pp. 329-335
    • Fawzy, A.1    Vashi, V.2    Chung, M.3
  • 13
    • 0032749958 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation
    • CHUNG M, VASHI V, PUENTE J, SWEENEY M, MEREDITH P: Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br. J. Clin. Pharmacol. (1999) 48:678-687.
    • (1999) Br. J. Clin. Pharmacol. , vol.48 , pp. 678-687
    • Chung, M.1    Vashi, V.2    Puente, J.3    Sweeney, M.4    Meredith, P.5
  • 14
    • 0027502569 scopus 로고
    • Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study
    • CHRISTENSEN MM, BENDIX HOLME J, RASMUSSEN PC et al.: Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand. J. Urol. Nephrol. (1993) 27:39-44.
    • (1993) Scand. J. Urol. Nephrol. , vol.27 , pp. 39-44
    • Christensen, M.M.1    Bendix Holme, J.2    Rasmussen, P.C.3
  • 15
    • 0028206741 scopus 로고
    • 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study
    • BENDIX HOLME J, CHRISTENSEN MM, RASMUSSEN PC et al.: 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scand. J. Urol. Nephrol. (1994) 28:77-82.
    • (1994) Scand. J. Urol. Nephrol. , vol.28 , pp. 77-82
    • Bendix Holme, J.1    Christensen, M.M.2    Rasmussen, P.C.3
  • 16
    • 0028285327 scopus 로고
    • A three month double-blind study of doxazosin as treatment of benign prostatic bladder outlet obstruction
    • CHAPPLE CR, CARTER P, CHRISTMAS TJ et al.: A three month double-blind study of doxazosin as treatment of benign prostatic bladder outlet obstruction. Br. J. Urol. (1994) 74:50-56.
    • (1994) Br. J. Urol. , vol.74 , pp. 50-56
    • Chapple, C.R.1    Carter, P.2    Christmas, T.J.3
  • 17
    • 0029002126 scopus 로고
    • Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study
    • FAWZY A, BRAUN K, LEWIS GP et al.: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol. (1995) 154:105-109.
    • (1995) J. Urol. , vol.154 , pp. 105-109
    • Fawzy, A.1    Braun, K.2    Lewis, G.P.3
  • 18
    • 0029024313 scopus 로고
    • Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose-response multicenter study
    • GILLENWATER JY, CONN RL, CHRYSANT SG et al.: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J. Urol. (1995) 154:110-115.
    • (1995) J. Urol. , vol.154 , pp. 110-115
    • Gillenwater, J.Y.1    Conn, R.L.2    Chrysant, S.G.3
  • 19
    • 0028805836 scopus 로고
    • Doxazosin in benign prostatic hyperplasia: Effects on blood pressure and urinary flow in normotensive and hypertensive men
    • KIRBY RS: Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology (1995) 46:182-186.
    • (1995) Urology , vol.46 , pp. 182-186
    • Kirby, R.S.1
  • 20
    • 0030248565 scopus 로고    scopus 로고
    • Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies
    • ROEHRBORN CG, SIEGEL RL: Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology (1996) 48:406-415.
    • (1996) Urology , vol.48 , pp. 406-415
    • Roehrborn, C.G.1    Siegel, R.L.2
  • 21
    • 0031021415 scopus 로고    scopus 로고
    • Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients
    • The Multicenter Study Group
    • LEPOR H, KAPLAN SA, KLIMBERG I et al.: Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J. Urol. (1997) 157:525-530.
    • (1997) J. Urol. , vol.157 , pp. 525-530
    • Lepor, H.1    Kaplan, S.A.2    Klimberg, I.3
  • 22
    • 0031749908 scopus 로고    scopus 로고
    • Tolerability of α-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: A pooled analysis of seven double-blind, placebo-controlled studies
    • KAPLAN SA, D'ALISERA PM: Tolerability of α-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies. J. Gerontol, A Biol. Sci. Med. Sci. (1998) 53:M201-M206.
    • (1998) J. Gerontol. A Biol. Sci. Med. Sci. , vol.53
    • Kaplan, S.A.1    D'alisera, P.M.2
  • 23
    • 0032851611 scopus 로고    scopus 로고
    • A randomized double-blind study assessing 4 versus 8 mg doxazosin for benign prostatic hyperplasia
    • MACDIARMID SA, EMERY RT, FERGUSON SF: A randomized double-blind study assessing 4 versus 8 mg doxazosin for benign prostatic hyperplasia. J. Urol. (1999) 162:1629-1632.
    • (1999) J. Urol. , vol.162 , pp. 1629-1632
    • Macdiarmid, S.A.1    Emery, R.T.2    Ferguson, S.F.3
  • 24
    • 0029554501 scopus 로고
    • Doxazosin in physiological and pharmacologically normotensive men with benign prostatic hyperplasia
    • KAPLAN SA, MEADE-D'ALISERA P, QUINONES S, SOLDO KA: Doxazosin in physiological and pharmacologically normotensive men with benign prostatic hyperplasia. Urology (1995) 146:512-517.
    • (1995) Urology , vol.146 , pp. 512-517
    • Kaplan, S.A.1    Meade-D'alisera, P.2    Quinones, S.3    Soldo, K.A.4
  • 25
    • 18244387257 scopus 로고    scopus 로고
    • Observational multicentric trial performed with doxazosin: Evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia
    • DEROSE AF, CARMIGNANI G, CORBU C: Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol. Int. (2002) 68:95-98.
    • (2002) Urol. Int. , vol.68 , pp. 95-98
    • Derose, A.F.1    Carmignani, G.2    Corbu, C.3
  • 26
    • 0033755524 scopus 로고    scopus 로고
    • Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia
    • ANDERSEN M, DAHLSTRAND C, HOYE K: Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur. Urol. (2000) 38:400-409.
    • (2000) Eur. Urol. , vol.38 , pp. 400-409
    • Andersen, M.1    Dahlstrand, C.2    Hoye, K.3
  • 27
    • 0034612429 scopus 로고    scopus 로고
    • Doxazosin GITS versus regular doxazosin in benign prostatic hyperplasia. Restoring urine flow and sexual function more easily
    • GRATZKE P, KIRBY RS: [Doxazosin GITS versus regular doxazosin in benign prostatic hyperplasia. Restoring urine flow and sexual function more easily]. MMW Fortschr Med. (2000) 142(26-27):40.
    • (2000) MMW Fortschr Med. , vol.142 , Issue.26-27 , pp. 40
    • Gratzke, P.1    Kirby, R.S.2
  • 28
    • 0035122753 scopus 로고    scopus 로고
    • A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia
    • KIRBY RS, ANDERSEN R, GRATZKE P, DAHLSTRAND C, HOYE K: A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. Br. J. Urol. Int. (2001) 87:192-200.
    • (2001) Br. J. Urol. Int. , vol.87 , pp. 192-200
    • Kirby, R.S.1    Andersen, R.2    Gratzke, P.3    Dahlstrand, C.4    Hoye, K.5
  • 29
    • 0036820774 scopus 로고    scopus 로고
    • Present and future pharmacotherapy for benign prostatic hyperplasia
    • DOGGRELL SA: Present and future pharmacotherapy for benign prostatic hyperplasia. Future Drugs (2002) 27:973-986.
    • (2002) Future Drugs , vol.27 , pp. 973-986
    • Doggrell, S.A.1
  • 30
    • 0035104828 scopus 로고    scopus 로고
    • Discontinuation of α-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction
    • BALDWIN KC, GINSBERG PC, HARKAWAY RC: Discontinuation of α-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urol. Int. (2001) 66:84-88.
    • (2001) Urol. Int. , vol.66 , pp. 84-88
    • Baldwin, K.C.1    Ginsberg, P.C.2    Harkaway, R.C.3
  • 31
    • 0034899266 scopus 로고    scopus 로고
    • Discontinuation of α-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia
    • BALDWIN KC, GINSBERG PC, ROEHRBORN CG, HARKAWAY RC: Discontinuation of α-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology (2001) 58:203-209.
    • (2001) Urology , vol.58 , pp. 203-209
    • Baldwin, K.C.1    Ginsberg, P.C.2    Roehrborn, C.G.3    Harkaway, R.C.4
  • 32
    • 0037253614 scopus 로고    scopus 로고
    • Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial
    • KIRBY RS, ROEHRBORN C, BOYLE P et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology (2003) 61:119-126.
    • (2003) Urology , vol.61 , pp. 119-126
    • Kirby, R.S.1    Roehrborn, C.2    Boyle, P.3
  • 33
    • 0030249241 scopus 로고    scopus 로고
    • Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
    • BOYLE P, GOULD AL, ROEHRBORN CG: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology (1996) 48:396-405.
    • (1996) Urology , vol.48 , pp. 396-405
    • Boyle, P.1    Gould, A.L.2    Roehrborn, C.G.3
  • 34
    • 0347882750 scopus 로고    scopus 로고
    • The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    • MCCONNEL JD, ROEHRBORN CG, BAUTISTA OM et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. (2003) 349:2387-2398.
    • (2003) N. Engl. J. Med. , vol.349 , pp. 2387-2398
    • Mcconnel, J.D.1    Roehrborn, C.G.2    Bautista, O.M.3
  • 35
    • 0037232329 scopus 로고    scopus 로고
    • A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia
    • KIRKBY RS: A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. Br. J. Urol. Int. (2003) 91:41-44.
    • (2003) Br. J. Urol. Int. , vol.91 , pp. 41-44
    • Kirkby, R.S.1
  • 36
    • 1942446146 scopus 로고    scopus 로고
    • Comparative efficacy of two α-adrenoceptor antagonists doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement
    • DE REIJKE TM, KLARSKOV P: Comparative efficacy of two α-adrenoceptor antagonists doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. Br. J. Urol. Int. (2004) 93:757-762.
    • (2004) Br. J. Urol. Int. , vol.93 , pp. 757-762
    • De Reijke, T.M.1    Klarskov, P.2
  • 37
    • 0035702786 scopus 로고    scopus 로고
    • Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: Decreased expression of heat shock proteins
    • HOOPER PL: Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins. Curr. Control Trials Cardiovasc. Med. (2001) 2:251-253.
    • (2001) Curr. Control Trials Cardiovasc. Med. , vol.2 , pp. 251-253
    • Hooper, P.L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.